Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

CVS Caremark Corporation : U.S. asks CVS about its prescription discount plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/17/2012 | 10:28pm CET

CVS Caremark Corp said it received requests for information about a prescription drug discount program it runs for uninsured or under-insured individuals from both the U.S. government and the Texas Attorney General.

In January, CVS received a subpoena from the U.S. Office of Inspector General requesting information about the company's Health Savings Pass program, CVS said in its 10k filing on Friday.

The company, which runs the CVS pharmacy chain and the CVS Caremark pharmacy benefits management service, said the request was connected to an investigation of possible false or otherwise improper claims for payment involving Health & Human Services programs.

In February, CVS received a civil investigative demand from Texas' Office of the Attorney General. That office requested a copy of information from the OIG subpoena and other information related to prescription drug claims submitted by CVS pharmacies to Texas Medicaid for reimbursement, the company said.

CVS said it would respond to the requests for information and cooperate with both investigations.

CVS markets its Health Savings Pass, which has a $15 annual fee, to people who do not have prescription drug coverage and to those who have limited coverage.

The Health Savings Pass lets patients fill 90-day prescriptions for 400 generic drugs for $11.99. Participants also get discounts such as 10 percent off visits at the CVS in-store health clinic, MinuteClinic and 10 percent off an annual flu shot.

The announcement comes about a month after CVS agreed to pay $5 million to settle charges of inaccurate pricing of some drugs for the elderly and disabled, ending a wide-ranging, multi-year probe into its business practices.

Shares of CVS closed down 28 cents at $44.27, after reaching a new high of $45 earlier in the day.

(Reporting by Jessica Wohl in Chicago; Editing by Richard Chang)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
12/14 CVS HEALTH : chief information officer resigns
12/14 CVS HEALTH : Foundation Announces Grant to Increase Access to Provider Education..
12/14 CVS HEALTH : Solera Health Expands Its Board of Directors with the Addition of H..
12/12 CVS HEALTH : 3 Reasons Why Florida Addiction Recovery Center CEO Is Wary Of $77 ..
12/11 CVS HEALTH : 3 Reasons Why Florida Addiction Recovery Center CEO Is Wary Of $77 ..
12/08 CVS expects U.S. Justice Department to handle review of Aetna deal
12/08 CVS HEALTH : A.M. Best Places Credit Ratings of SilverScript Insurance Company U..
12/08 CVS HEALTH : Greg's Pharmacy, Bluffton, will become a CVS Pharmacy
12/07 MYERS INDUSTRIES : Names Chris DuPaul as Group President, Distribution
12/07 CVS HEALTH : Meningitis B Vaccine Available to Students, Faculty and Staff at UM..
More news
News from SeekingAlpha
12/14 The Next 20 Dividend Achievers Absolutely Trounce The Market
12/14 WALGREENS BOOTS ALLIANCE : Trading At A Bargain
12/13 The Value Of Reliability And Why Omega Healthcare Is A Value Trap
12/13 I'm Sticking With CVS And Walgreens, My Last Two Losers
12/11 CVS AND AETNA : The Worst Of Sick-Care Under One Roof
Financials ($)
Sales 2017 184 B
EBIT 2017 10 083 M
Net income 2017 5 255 M
Debt 2017 24 517 M
Yield 2017 2,77%
P/E ratio 2017 14,27
P/E ratio 2018 12,59
EV / Sales 2017 0,53x
EV / Sales 2018 0,49x
Capitalization 72 551 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 86,1 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-7.38%72 551
WALGREENS BOOTS ALLIANCE-13.55%71 028
EXPRESS SCRIPTS HOLDING CO-0.93%38 836
MCKESSON CORPORATION6.81%32 357
AMERISOURCEBERGEN CORP.9.90%19 296
CARDINAL HEALTH INC-18.72%19 093